Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.56 |
| ▸ | MC4R | P32245 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8108453 | 1.00 | CYP2D6 (0.63) | CYP2D6CHRNA7MC4ROPRM1OPRK1 | |
| SCHEMBL7264542 | 0.79 | CYP2D6 (1.00) | CYP2D6MC4ROPRM1OPRK1OPRL1 | |
| SCHEMBL6706135 | 0.79 | CYP2D6 (1.00) | CYP2D6MC4ROPRM1OPRK1OPRL1 | |
| SCHEMBL16226061 | 0.79 | CYP2D6 (1.00) | CYP2D6MC4ROPRM1OPRK1OPRL1 | |
| SCHEMBL8099850 | 0.77 | CYP2D6 (0.70) | CYP2D6MC4ROPRM1OPRK1OPRL1 | |
| SCHEMBL1586528 | 0.77 | CYP2D6 (0.70) | CYP2D6MC4ROPRM1OPRK1OPRL1 | |
| SCHEMBL4601165 | 0.77 | CYP2D6 (0.70) | CYP2D6MC4ROPRM1OPRK1OPRL1 | |
| SCHEMBL19613500 | 0.77 | CYP2D6 (0.70) | CYP2D6MC4ROPRM1OPRK1OPRL1 | |
| SCHEMBL23850144 | 0.75 | CYP2D6 (0.83) | CYP2D6MC4ROPRM1OPRK1OPRL1 | |
| SCHEMBL8983562 | 0.75 | CYP2D6 (0.83) | CYP2D6MC4ROPRM1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6642231-B2 | Antineoplastic agents, treatment for neuronal injury and degeneration | AVENTIS PHARMACEUTICALS INC. | 2003-11-04 | — | — | US | disclosed |
| EP-1056744-B1 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMA INC (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030105098-A1 | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | AVENTISUB II INC. | 2003-06-05 | — | — | US | disclosed |
| US-6479487-B1 | INHIBIT CYCLIN DEPENDENT KINASES, PARTICULARLY CDK-2; ANTIAPOPTOSIS AGENT; INHIBITS DEVELOPMENT OF NEOPLASMS | AVENTIS PHARMACEUTICALS INC. | 2002-11-12 | — | — | US | disclosed |
| EP-1056744-A1 | 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | Aventis Pharmaceuticals Inc. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999043675-A1 | 6,9-DISUBSTITUTED 2-[TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMACEUTICALS INC. (US) | 1999-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105098-A1 | 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines | CDK6, CDK5, CDK2 | CYP2D6 1607/4885CHRNA7 3390/4885MC4R 3700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.